Sustainability
As a pharmaceutical and healthcare company, STADA is responsible for ensuring the group-wide safety of its products and thus also the safety of patients. That’s what SDG 17 is all about.
Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
Explore STADA
Your opportunity for success with STADA
We are looking for qualified employees who drive our company forward with their specialist knowledge and commitment. We offer appealing conditions with diverse and exciting tasks as well as good career prospects and a motivating working environment.
Today's spotlight is on my team: Watch the video to see how we drive STADA Group's unique growth culture every day!
By Simone Berger,
Attending UEGW this year brought back some great memories.
By Alexey Chekmarev,
🌱 Experience Hemofarm Day 25/10 with Culture and People colleagues, at the ESGfestival
By Cuc Tong Thu, at Hemofarm A.D.
In 2021 we dreamt that in the foreseeable future we would create a new state of the art / future-ready packaging ...
By Miguel Pagan, Chief Technical Officer / Member at STADA Group
Spent two amazing days in Turda for the new production and supply chain hub openning Stada România.
By Catalina Medaru, Global Category Manager at STADA Group
STADA Voices
Latest news
10/10/2024
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
26/07/2024
European Commission approval to expand label & patient group for IgA Nephropathy orphan medicine
24/06/2024
STADA Health Report 2024: Satisfaction with healthcare systems continues to decline
28/05/2024
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, EU and UK
21/05/2024
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
10/05/2024
Xbrane, STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US
10/01/2024
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
These moments remind me that while we strive to deliver innovative biologic therapies #caringforpeopleshealth, congresses like UEGW offer something equally valuable – the opportunity to meet old friends and make new ones. And it’s great that this time we could “catch” more new opportunities to help patients than just those two fish!